News and Events

It is with great honor and pleasure that we report that Dr. Scott L. Friedman has joined MAX BioPharma’s Scientific Advisory Board. Dr. Friedman is...

MAX BioPharma and Technomark Life Sciences announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, Oxy210,...

MAX BioPharma, Inc. and Revilico, Inc. announced their collaboration in studying the mechanisms of action, performing lead optimization, and...

MAX BioPharma Reports on Oxy210’s Inhibition of Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During...

MAX BioPharma reports on the Inhibition of Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells by its Oxysterol Drug...